Introduction
============

Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL), accounts for 30-40% of adult cases of NHL. Although significant developments and progress have been made in the treatment of aggressive lymphoma in recent decades, 40% of patients with DLBCL still die of disease recurrence [@B1].

A number of clinical trials have found that hepatitis B virus (HBV) infection may lead to a poorer prognosis and response to standard chemotherapy in DLBCL; however, these results are controversial. Overall survival (OS) and progression free survival (PFS) have mainly been used to evaluate prognosis in DLBCL. Deng, Guo and Shan reported that HBV infection may lead to poorer OS [@B2]-[@B4], while Law and Zhang reported the opposite result. However, many researchers use different criteria to evaluate PFS [@B5], [@B6]. The rates of complete response (CR) and progressive disease (PD) can more objectively reflect the response of patients to standard chemotherapy [@B1]. Most related studies have not indicated a significant positive relationship between HBV infection and the response to standard chemotherapy in patients with DLBCL [@B3]-[@B5], [@B7], [@B8]. However, Deng and Feng demonstrated HBV infection negatively affected the response to chemotherapy [@B2], [@B9]. Additionally, while the clinical outcomes of patients with DLBCL can be predicted using other indices, such as the International Prognostic Index (IPI), serum lactate dehydrogenase (LDH) and the presence of B symptoms, these indices have not been consistently identified as prognostic factors across all studies.

There are estimated to be more than 350 million carriers of persistent HBV worldwide, one third of who develop serious sequelae such as cirrhosis, liver failure and hepatocellular carcinoma (HCC). The increased risk of malignant changes is a serious threat to the health of HBV carriers [@B10]. Therefore, the relationship between HBV infection and the prognosis of DLBCL is an important issue, especially in Asian-Pacific regions where the prevalence of HBV is high.

Further assessment of the relationship between chronic HBV infection and DLBCL may contribute to our knowledge on the pathogenesis of DLBCL, and more importantly, indicate the importance of anti-viral treatment in HBV-infected patients with DLBCL. Thus, we conducted a meta-analysis to explore the relationship between HBV infection and disease progression in DLBCL.

Methods
=======

Inclusion and exclusion criteria
--------------------------------

Randomized controlled trials and retrospective studies published up to February 2019 were included in this meta-analysis if they focused on the prognosis or other clinical indices of DLBCL among patients with or without chronic HBV infection. DLBCL had to be diagnosed by cytological examination or pathological examination according to the World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues [@B1]. DLBCL was clinically staged according to the Ann Arbor staging criteria [@B11]. Chronic HBV infection was defined as serum HBV surface antigen (HBsAg) positivity above the baseline. The risks were reported or calculated from the primary data as OR with corresponding 95% CIs. The quality of all included studies was evaluated using the Newcastle-Ottawa Scale (NOS) [@B12]. Studies with the NOS of 5 or less were excluded for further analysis. Disagreements were resolved by discussion between the two investigators (X.R. and H.W.).

Literature search strategy
--------------------------

A systemic review was conducted by strictly following the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines for reporting of systematic review and meta-analysis [@B13]. We carried out literature searches of the PubMed, EMBASE and Cochrane Central Register of Controlled Trials (CENTRAL/CCTR) databases and Chinese databases including WANFANG, CNKI and VIP. We used the keywords "HBV", "HBsAg", "Hepatitis B", "Hepatitis B virus", "Dane particle" AND "DLBCL", "Diffuse Large B cell lymphoma". The specific literature search strategy is listed in Table [1](#T1){ref-type="table"}. Two authors (X.R. and H.W.) independently screened all retrieved titles and abstracts and selected studies for further screening. Disagreements were resolved by discussion between the two investigators.

Data extraction
---------------

Two authors (X.R. and H.W.) independently extracted the data from the included trials. We identified the trials using the name of the first author and the year in which the trial was first published. We extracted data on the outcomes of HBsAg-positive and -negative patients. In order to confirm that each trial met the inclusion criteria for this meta-analysis, data on the assessment and treatment of DLBCL and chronic HBV infection were also extracted from each study. Disagreements were resolved by discussion between the two investigators.

Data analysis
-------------

We used Engauge Digitizer 4.1 to calculate the 2-year and 5-year OS and PFS follow-up data from the published survival curves if the exact data was not given in the study. Revman Manager 5.3 was used to conduct the meta-analysis. Hazard ratios (HRs) were used to compare OS and PFS, and OR values and 95% CIs were used to assess other indices. Inter-study heterogeneity was measured using the Chi-squared test and I^2^ metric with significance set at *P* \< 0.1 or I^2^ \> 50%. A fixed-effect model should be utilized in the absence of significance heterogeneity; otherwise a random-effect model should be applied. Sensitivity analyses were employed to determine if there was a possible source of heterogeneity. The Z test was employed to assess the overall effect; *P*-values less than 0.05 were considered significant. Funnel plots were used to analyze publication bias.

Results
=======

Description of studies
----------------------

We conducted a strict literature search following the established search strategies. In total, 362 clinical trials, from 1977 so far, were retrieved after excluding duplications. Among them, 330 were excluded after screening the titles and abstracts, and 32 were evaluated in detail. And finally, only 15 trials from the first report in 2012 updating to February 2019 met the eligibility criteria for this meta-analysis. The flowchart summarizing the literature search is shown in Figure [1](#F1){ref-type="fig"}.

Quality Assessment
------------------

The quality of all 15 eligible clinical trials was evaluated using the NOS. Thirteen trials were high quality (scores over 6) and one trial scored 6 (moderate quality). The remaining trials [@B14],[@B15] with low quality (score of 5) were excluded from the meta-analysis. The specific details are shown in Table [2](#T2){ref-type="table"}.

Characteristics of included studies
-----------------------------------

The characteristics of the thirteen trials that qualified for this meta-analysis are listed in Table [S1](#SM0){ref-type="supplementary-material"} [@B2], [@B3], [@B5], [@B6], [@B8], [@B9], [@B16]-[@B22]. Ten of the thirteen trials reported using the standard therapy for DLBCL of CHOP or R-CHOP. Therapy for HBV infection was only mentioned in three trials: Deng\'s (2015) [@B2], Guo\'s (2015) [@B3] and Law\'s studies (2015) [@B5].

Chronic HBV infection and prognosis in DLBCL
--------------------------------------------

Compared to patients who did not have chronic HBV infection, DLBCL patients with chronic HBV infection had significantly poorer OS and PFS. For OS, the HR was 1.54 at 2 years (95% CI 1.23-1.92, *P* \< 0.001, Figure [2](#F2){ref-type="fig"}A) and 1.79 at 5 years (95% CI 1.48-2.17, *P* \< 0.001, Figure [2](#F2){ref-type="fig"}B). For PFS, the HR was 1.44 at 2 years (95% CI 1.14-1.81, *P* =0.002, Figure [2](#F2){ref-type="fig"}C) and 1.34 at 5 years (95% CI 1.02-1.75, *P* =0.03, Figure [2](#F2){ref-type="fig"}D).

Chronic HBV infection and response to chemotherapy in DLBCL
-----------------------------------------------------------

DLBCL patients with chronic HBV infection had a higher rate of PD than patients without chronic HBV infection (OR 2.08, 95% CI 1.34-3.24, *P* =0.001, Figure [3](#F3){ref-type="fig"}B). DLBCL patients with chronic HBV infection also had a lower CR rate (OR 0.48, 95% CI 0.34-0.68, *P* \<0.001, Figure [3](#F3){ref-type="fig"}A).

Chronic HBV infection and the clinical features of DLBCL
--------------------------------------------------------

In the eleven trials that reported the age of onset of DLBCL, patients with chronic HBV infection were significantly younger when diagnosed with DLBCL than patients without chronic HBV infection (OR 2.19, 95% CI 1.75-2.74, *P* \<0.001, Figure [4](#F4){ref-type="fig"}A), they were more likely to be diagnosed younger than 60-years-old. Patients with chronic HBV infection were also more likely to have advanced DLBCL (stage 3 or 4) at diagnosis (OR 1.85, 95% CI 1.55-2.23, *P* \<0.001, Figure [4](#F4){ref-type="fig"}B) and significantly more likely to have elevated LDH (OR 1.40, 95% CI 1.14-1.73, *P* =0.002, Figure [4](#F4){ref-type="fig"}C).

However, there was no significant difference in having B symptom (OR 1.31, 95% CI 0.71-2.42, *P* =0.39, Figure [4](#F4){ref-type="fig"}D), IPI score (IPI score \> 2: OR 0.93, 95% CI 0.62-1.41, *P* =0.74, Figure [4](#F4){ref-type="fig"}E) or the number of extra-nodal sites (more than one extra-nodal site vs. no sites or one extra-nodal site: OR 1.13, 95% CI 0.88-1.44, *P* = 0.34, Figure [4](#F4){ref-type="fig"}F) between DLBCL patients with and without chronic HBV infection. HBV infection was not associated with the subtype of DLBCL (non-GCB vs. GCB: OR 0.94, 95% CI 0.48-1.83; *P* = 0.85; Figure [4](#F4){ref-type="fig"}G). All the detailed results are listed in Table [3](#T3){ref-type="table"}. Additionally, funnel plots were used to analyze publication bias of each comparison and the results were shown in Figure [S1](#SM0){ref-type="supplementary-material"}.

Discussion
==========

This meta-analysis found that chronic HBV infection is associated with the prognosis of DLBCL. Patients with chronic HBV infection had significantly poorer 2-year and 5-year OS and PFS. Remarkably, DLBCL patients with HBsAg-seropositive also had poorer responses to standard chemotherapy, with a higher PD rate and lower CR rate, than their HBsAg-seronegative counterparts. Additionally, the patients with chronic HBV infection tended to be diagnosed with DLBCL at a younger age, had more advanced disease (stage 3 or 4) at diagnosis, and were more likely to have elevated LDH. However, there was no evidence that chronic HBV infection was related to the onset of B symptoms, IPI score, the number of extra-nodal sites or the subtype of DLBCL.

Several systematic reviews have focused on the relationship between the incidence of DLBCL and HBV infection. And one most recent review, which was updated in March 2018, found patients with DLBCL had a higher risk of HBV infection than a control group of healthy individuals [@B23]. However, there is no evidence in support of an association between HBV infection and T cell NHL [@B24]-[@B27]. Therefore, we infer that B cells may play a more important role in the pathogenesis of HBV-associated NHL than T cells. Moreover, compared to patients with HBV seronegative, DLBCL patients with HBV seropositive have a poorer prognosis, even after receiving anti-viral therapy to reduce the potential risk of HBV reactivation that may lead to liver dysfunction [@B2], [@B3]. This observation may imply that HBV infection can negatively affect prognosis in DLBCL via processes that are not directly related to the risk of liver dysfunction and reactivation of hepatitis conferred by chemotherapy. Our data indicates that HBV may promote the progression of HBV-associated DLBCL via a number of other mechanisms beyond the direct effects of replication of the HBV virus. These findings provide a hint that HBV may possibly play a role in pathogenesis of DLBCL; however, unfortunately few studies have focused on this issue.

Although it is commonly assumed that the pathogenesis of HBV-associated DLBCL and HCV-associated B cell NHL are similar, there are several differences between these diseases [@B28]. HBV, a typical hepadnavirus, has a remarkably unique viral pathogenesis compared to HCV, a member of the family *Flaviviridae*. Even more intriguingly, unlike HBV infection and DLBCL, no associations have been reported between a poorer prognosis in HCV-associated B cell NHL after antiviral chemotherapy [@B24]. Therefore, we speculate that---unlike HCV infection---HBV infection may influence the incidence and progression of DLBCL in several ways.

Firstly, HBV infection may induce genetic changes in DLBCL. HBV DNA has been confirmed to integrate into the host genome, and HBV DNA has been detected in the tumor tissues of patients with DLBCL [@B2]. A recent study reported that some of the specific gene mutations observed in the tumor cells of HBV-associated DLBCL were regulated by BCL6 and FOXO1 [@B29]. This indicates that HBV-induced gene mutations may play a role in both the initiation and progression of DLBCL.

Secondly, Deng and colleagues found that in HBsAg-positive DLBCL patients, almost all amino acid sequences of heavy and light chain complementarity determining region 3 exhibited a high homology to antibodies specific for HBsAg. About 90% of IgHV and IgLV genes were mutated in these patients, which suggests that HBV-associated DLBCL may arise from HBV antigen-selected B cells [@B2].

This finding suggests that long-term antigenic stimulation caused by chronic HBV infection could contribute to the initiation of DLBCL. The inference is supported by two findings: firstly, an increased risk of B-NHL is not observed among individuals who had been infected with or vaccinated against HBV [@B7], [@B30], [@B31]. Secondly, HBsAg and HBcAg can be detected in the tumor tissues of patients with DLBCL and chronic HBV infection. It is hard to achieve serological conversion of HBsAg in most cases, even after administering effective anti-viral therapy against HBV. The antigen-stimulation hypothesis may explain why patients with DLBCL and HBV infection have a poorer prognosis, even after receiving anti-viral therapy. Long-term presentation of HBsAg in the serum of patients with chronic HBV infection may lead to immune tolerance and may thus worsen the prognosis of DLBCL [@B32]-[@B34]. Moreover, the HBsAg titer may also play a decisive role in the interplay between the virus and immune system. Therefore, we recommend that quantitative measurement of serum HBsAg is necessary for HBV-infected patients with DLBCL in future studies. The introduction of immunomodulatory strategies, which may break the immune tolerance induced by HBsAg, may possibly boost the response of DLBCL to chemotherapy and improve prognosis in patients with chronic HBV infection. However, the specific mechanisms by which HBV induces the initiation and promotes the progression of DLBCL remain unknown and need further investigation.

There are some limitations to this meta-analysis. Firstly, publication bias may exist as only published trials were included (Figure [S1](#SM0){ref-type="supplementary-material"}); it is not known whether related unpublished trials exist. Secondly, 10 of the all the included clinical trials, which focused on the prognosis of HBV-associated DLBCL, were case-control studies. Thirdly, all of the related clinical trials were conducted in regions where the prevalence of HBV is high. Thus, all of these factors may bias the systematic review.

In conclusion, this meta-analysis is the first demonstration that chronic HBV infection leads to poorer outcomes and a poorer prognosis in DLBCL. This study suggests that in addition to anti-viral therapy, more attention should be paid to the virological effects of HBV, especially HBsAg, during the progression of DLBCL.
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![Forest plots comparing overall survival (OS) and progression-free survival (PFS) between DLBCL patients with chronically HBsAg seropositive and with HBsAg seronegative. (A) Two-year OS (HR 1.54, 95% CI 1.23-1.92, *P* \< 0.001); (B) Five-year OS (HR 1.79, 95% CI 1.48-2.17, *P* \< 0.001); (C) Two-year PFS (HR 1.44, 95% CI 1.41-1.81, *P* = 0.002); (D) Five-year PFS (HR 1.34, 95% CI 1.02-1.75, *P* = 0.03).](jcav10p3450g002){#F2}

![Forest plots comparing the response to primary chemotherapy for DLBCL patients with chronically HBsAg seropositive and with HBsAg seronegative. (A) Complete response (CR) rate (OR 0.48, 95% CI 0.34-0.68, *P* \< 0.001); (B) Progressive disease (PD) rate (OR 2.08, 95% CI 1.34-3.24, *P* = 0.001).](jcav10p3450g003){#F3}
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Forest plots comparing the clinical features of DLBCL patients with chronically HBsAg seropositive and with HBsAg seronegative. (A) Age of onset of DLBCL, over 60-years-old (OR 2.19, 95% CI 1.75-2.74; *P* \< 0.001). (B) Disease stage at diagnosis, stage 3 or 4 (OR 1.85, 95% CI 1.55-2.23; *P* \< 0.001). (C) Elevated LDH (OR 1.40, 95% CI 1.14-1.73, *P* =0.002). (D) Presence of B symptoms (OR 1.31, 95% CI 0.71-2.24, *P* =0.39). (E) IPI score, 2 or higher (OR 0.93, 95% CI 0.62-1.41, *P* = 0.74). (F) More than two sites of extra-nodal metastasis (OR 1.13, 95% CI 0.88-1.44, *P* = 0.34). (G) Subtype of DLBCL, non-GCB (OR 0.94, 95% CI 0.48-1.83, *P* = 0.85).
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###### 

Search strategy

  Database                                                                                                                  Period    Search strategy
  ------------------------------------------------------------------------------------------------------------------------- --------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  PubMed                                                                                                                    -2019.2   ((( \"Lymphoma, Large B-Cell, Diffuse/epidemiology\"\[Mesh\] OR \"Lymphoma, Large B-Cell, Diffuse/etiology\"\[Mesh\] OR \"Lymphoma, Large B-Cell, Diffuse/genetics\"\[Mesh\] OR \"Lymphoma, Large B-Cell, Diffuse/immunology\"\[Mesh\] OR \"Lymphoma, Large B-Cell, Diffuse/microbiology\"\[Mesh\] OR \"Lymphoma, Large B-Cell, Diffuse/virology\"\[Mesh\] ) AND ((\"HBV\"\[TIAB\] OR \"HBSAG\"\[TIAB\] OR \"Hepatitis B\"\[TIAB\] OR \"Hepatitis B virus\"\[TIAB\] OR \"Dane Particle\"\[TIAB\]) NOT Hemoglobin-vesicles\[TIAB\])) OR ((( \"Hepatitis B virus/complications\"\[Mesh\] OR \"Hepatitis B virus/pathogenicity\"\[Mesh\] ) OR ( \"Hepatitis B, Chronic/complications\"\[Mesh\] OR \"Hepatitis B, Chronic/epidemiology\"\[Mesh\] ) OR ( \"Hepatitis B/complications\"\[Mesh\] OR \"Hepatitis B/epidemiology\"\[Mesh\] OR \"Hepatitis B/physiopathology\"\[Mesh\] OR \"Hepatitis B/statistics and numerical data\"\[Mesh\] )) AND ("Diffuse"\[TIAB\] AND ("Large B-Cell"\[TIAB\] OR "LARGE CELL" OR "B CELL") AND "Lymphoma"\[TIAB\])) OR (("Large B-Cell"\[TIAB\] OR "LARGE CELL" OR "B CELL") AND "Lymphoma"\[TIAB\]) AND ((\"HBV\"\[TIAB\] OR \"HBSAG\"\[TIAB\] OR \"Hepatitis B\"\[TIAB\] OR \"Hepatitis B virus\"\[TIAB\] OR \"Dane Particle\"\[TIAB\]) NOT Hemoglobin-vesicles\[TIAB\]))
  EMBASE                                                                                                                    -2019.2   \#1 exp hepatitis b/ or exp hepatitis b, chronic/
  \#2 exp Hepatitis B virus/                                                                                                          
  \#3 exp Lymphoma, Large B-Cell, Diffuse/                                                                                            
  \#4 (HBV or Hepatitis B or Hepatitis B virus).ti.                                                                                   
  \#5 (Diffuse and Large B-Cell and Lymphoma).ti.                                                                                     
  \#6 \#1 or \#2                                                                                                                      
  \#7 \#5 and \#6                                                                                                                     
  \#8 \#3 and \#4                                                                                                                     
  \#9 \#4 and \#5                                                                                                                     
  \#10 \#7 or \#8 or \#9                                                                                                              
  The Cochrane Central Register of Controlled Trials (CENTRAL/CCTR) in The Cochrane Library                                 -2019.2   \#1 MeSH descriptor: \[Hepatitis B\] explode all trees
  \#2 MeSH descriptor: \[Hepatitis B virus\] explode all trees                                                                        
  \#3 MeSH descriptor: \[Lymphoma, Large B-Cell, Diffuse\] explode all trees                                                          
  \#4 Diffuse and (\"Large B-Cell\" or \"LARGE CELL\" or \"B CELL\") and \*:ti,ab,kw (Word variations have been searched)             
  \#5 hbv or \"hepatitis b\" or \"hepatitis b virus\" or \"hbsag\":ti,ab,kw (Word variations have been searched)                      
  \#6 (\#1 or \#2) and \#4                                                                                                            
  \#7 \#3 and \#5                                                                                                                     
  \#8 \#4 and \#5                                                                                                                     
  \#9 (\#6 or \#7 or \#8)                                                                                                             

###### 

Quality assessment for studies.

  Study           Quality indicators from Newcastle-Ottawa scale   Score                                     
  --------------- ------------------------------------------------ ------- --- --- -- --- --- -- --- --- --- ---
  Chai 2016       ★                                                ★           ★      ★          ★           5
  Deng 2015 \*    ★                                                ★       ★   ★      ★   ★      ★   ★   ★   9
  Feng 2016       ★                                                ★           ★          ★      ★   ★   ★   7
  Guo 2015 \*     ★                                                ★       ★   ★      ★   ★      ★   ★   ★   9
  Guo 2018        ★                                                ★           ★      ★   ★      ★   ★   ★   8
  Huang 2012      ★                                                ★           ★      ★   ★      ★   ★       7
  Law 2015        ★                                                ★           ★      ★   ★      ★   ★   ★   8
  Pang 2018       ★                                                ★           ★      ★          ★           5
  Shan 2016       ★                                                ★           ★      ★   ★      ★   ★       7
  Wang 2016       ★                                                ★           ★                 ★   ★   ★   6
  Wang 2018       ★                                                ★           ★      ★          ★   ★   ★   7
  Wei 2015        ★                                                ★           ★          ★      ★   ★   ★   7
  Wei 2014        ★                                                ★           ★      ★   ★      ★   ★       7
  Zhang 2012      ★                                                ★           ★      ★   ★      ★   ★   ★   8
  Zheng 2014 \*   ★                                                ★       ★   ★      ★   ★      ★   ★   ★   9

For case-control studies,1 indicates that the case is definite with independent validation; 2 the case is consecutive or representative of population; 3 the control is from community; 4 the control is HBsAg seronegative; 5a study controls for receiving standard treatment; 5b studies control for no HIV infection; 6 the case\'s exposure is ascertained by secure record or blinded-interview; 7 the ascertainment for case and control are the same; 8 Non-Response rate of both group is same. For cohort studies (\*): For cohort studies, 1 indicates exposed cohort truly representative, 2 the non-exposed cohort drawn from the same hospital,3 ascertainment of exposure by secure record or structured interview,4 outcome of interest was not present at start of study, 5a cohorts comparable on basis of all patients receiving standard treatment, 5b study controls for no HIV infection, 6 quality of outcome assessment, 7 follow-ups long enough for outcomes to occur;8 complete follow-up.

###### 

Comparison clinical outcomes between DLBCL patients with and without HBsAg-seropositive

  Clinical factors                                             Studies                         Total   Effect Estimate         p value                 
  ------------------------------------------------------------ ------------------------------- ------- ----------------------- ----------------------- ---------
  Prognosis (figure [2](#F2){ref-type="fig"})                  Two-year OS (A)                 7       1469                    1.54\[1.23,1.92\]^\*^   \<0.001
  Five-year OS (B)                                             8                               1756    1.79\[1.48,2.17\]^\*^   \<0.001                 
  Two-year PFS (C)                                             4                               1069    1.44\[1.14,1.81\]^\*^   0.002                   
  Five-year PFS (D)                                            3                               834     1.34\[1.02,1.75\]^\*^   0.03                    
  Response to chemotherapy (figure [3](#F3){ref-type="fig"})   CR (A)                          10      2389                    0.48\[0.34,0.68\]       \<0.001
  PD (B)                                                       7                               1986    2.08\[1.34.3.24\]       0.001                   
  Clinical features (figure [4](#F4){ref-type="fig"})          Diagnosed Younger than 60 (A)   10      2585                    2.19\[1.75,2.74\]       \<0.001
  Stage 3 or 4 (B)                                             12                              3150    1.85\[1.55,2.23\]       \<0.001                 
  LDH Level Elevation (C)                                      9                               2200    1.40\[1.14,1.73\]       0.002                   
  B Symptoms (D)                                               4                               1159    1.31\[0.71,2.42\]       0.39                    
  IPI Score over 2                                             8                               2037    0.93\[0.62,1.41\]       0.74                    
  Extra-nodal sites ≥ 2 (F)                                    8                               2028    1.13\[0.88, 1.44\]      0.34                    
  Non-GCB vs. GCB (G)                                          5                               1018    0.94\[0.48,1.83\]       0.85                    

\* The result is estimated by Hazard ratio.
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